Rockwell Medical (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency anemia, secondary hyperparathyroidism and hemodialysis in the U.S. and throughout the world.
As an established manufacturer and leader in delivering high-quality, innovative drug therapies and hemodialysis concentrates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products used to save and sustain human life, removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Our life-sustaining products are not considered discretional in nature nor their use capable of being deferred.
